We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Arecor Therapeutics Plc | LSE:AREC | London | Ordinary Share | GB00BMWLM973 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 1.00 | 0.73% | 137.50 | 10,576 | 12:42:40 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 135.00 | 140.00 | 137.50 | 136.50 | 136.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 3.54M | -9.26M | -0.3024 | -4.55 | 42.11M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 12:42:32 | O | 10,000 | 137.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 29/4/2024 | 07:00 | UK RNS | Arecor Therapeutics PLC Notice of results |
| 23/4/2024 | 11:02 | ALNC |  Arecor chief financial officer to leave in July after five years |
| 23/4/2024 | 07:00 | UK RNS | Arecor Therapeutics PLC BOARD CHANGE |
| 12/3/2024 | 12:16 | ALNC | Arecor to develop "holy grail" diabetes treatment with partner TRx |
| 12/3/2024 | 08:58 | UK RNS | Arecor Therapeutics PLC Arecor and TRx Biosciences research collaboration |
| 12/3/2024 | 07:00 | UK RNS | Arecor Therapeutics PLC Arecor and TRx Biosciences research collaboration |
| 29/2/2024 | 19:42 | ALNC | EARNINGS AND TRADING: East Star, Getech strike Kazakhstan JV |
| 29/2/2024 | 07:00 | UK RNS | Arecor Therapeutics PLC Arecor announces launch of Ogluo® in Netherlands |
| 01/2/2024 | 14:24 | ALNC | Arecor Therapeutics hails Arestat as 2023 performance "strong" |
| 01/2/2024 | 07:00 | UK RNS | Arecor Therapeutics PLC Year End Trading Update |
Arecor Therapeutics (AREC) Share Charts1 Year Arecor Therapeutics Chart |
|
1 Month Arecor Therapeutics Chart |
Intraday Arecor Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/3/2024 | 19:58 | Arecor | 279 |
| 27/2/2024 | 09:01 | Current weakness | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 01/5/2024 09:20 by Arecor Therapeutics Daily Update Arecor Therapeutics Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker AREC. The last closing price for Arecor Therapeutics was 136.50p.Arecor Therapeutics currently has 30,625,654 shares in issue. The market capitalisation of Arecor Therapeutics is £42,110,274. Arecor Therapeutics has a price to earnings ratio (PE ratio) of -4.55. This morning AREC shares opened at 136.50p |
Posted at 28/2/2024 11:14 by stupidboypike We have also been promised initial results of the AT278 trial in H1 this year. The last time we got some AT278 results it triggered the share price going from 220 to 400 in very short order, so as usual, "you pays your money and you takes your choice"Best regards SBP |
Posted at 27/2/2024 13:55 by jones1961 Please don't waste your time here Supernumerary. Arecor IPO was at 2.20, it hit a high of above 4 pounds, and was still above IPO price 9 months ago...I believe it is just what I say it is |
Posted at 27/2/2024 11:40 by stupidboypike Jones1961 many thanks for that information, it's very helpful. Like you I believe that this price represents an extraordinary opportunity, but I am fully invested. Best regards SBP |
Posted at 01/2/2024 07:39 by nchanning Seems to be the same problem with every good growth share on AIM at the moment . Market knows there's not enough cash , so it keeps drifting lower before the placing . Then management don't want to dilute too much at very low valuation so they don't raise enough cash again , and the same cycle happens again |
Posted at 24/1/2024 09:52 by mdchand hxxps://www.researchTrinity Delta view: Sanofi’s acquisition of INBRX-101 fits in with its portfolio growth strategy and its focus and reputation in rare diseases, and the $1.7bn+ deal value underscores INBRX-101’s attractiveness. For Arecor this is further commercial validation for its formulation expertise and ability to create clearly differentiated assets. INBRX-101 is Arecor’s second most advanced partnered asset, behind biosimilar AT220 (believed to be Fresenius Kabi’s tocilizumab) which launched in Europe in H223; both emerged from a technology formulation partnership. Such partnerships are a low-risk business model generating nearterm revenues; Arecor receives research fees from day one of any formulation development collaboration under which it reformulates and develops optimised versions of a partner’s own products or product candidates. Should these convert to licences, as with AT220 and INBRX-101, there is potential for meaningful financial upside via milestones and future commercialisation income (royalties or similar). For more detail on Arecor’s investment case see our November 2023 Outlook. Our valuation remains £179m, equivalent to 583p per share. |
Posted at 11/12/2023 18:38 by gleach23 Ignoring the UT closing trade of 1 share, some more chunky trades reported after the bell of 55,000 shares @ 189p and 59,348 @ 190p |
Posted at 04/12/2023 13:16 by 127tolmers As foreshadowed in the TD report which calculated potential values of such a deal:Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces a co-development and exclusive licence option agreement with a leading global medical products company for a high-value, ready-to-dilute (“RTD”) oncology product from Arecor’s in-house Specialty Hospital pipeline. Under the terms of the agreement, Arecor and its partner will conduct further co-development and regulatory work with Arecor eligible to receive potential developmental milestones. The agreement includes an option for the partner to be granted an exclusive, worldwide license to further develop and commercialise the product, with Arecor eligible to receive milestones and royalty payments. Arecor has developed a proprietary RTD form of a lyophilized powder product using its formulation technology platform, Arestat™. This novel, liquid, RTD formulation of an existing ‘blockbuster&# |
Posted at 01/12/2023 17:28 by gleach23 That's some trade for AREC reported late today - 60,735 @ 191.54p |
Posted at 29/11/2023 10:10 by stupidboypike The lovely thing about these deals is there is no risk, the customer pays for development ( I'm sure with a small profit margin added) and if it's successful we get income, if not we lose nothing. They have added 11 since the IPO, can't help thinking our share price should be higher. Even if our blockbuster insulins fail to delight, I think these partnerships in time will make Arecor a very profitable company.Might add a few in due course. Best regards SBP |
Posted at 28/6/2023 08:04 by alloa2003 As the AREC treatments are effectively improvements on existing treatments you would assume there would be little concern about toxicity etc in the trials. I would therefore be surprised if the initial feedback from the treatment is not confirmed via the trials? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
